Study of Liso-cel for mantle cell lymphoma after market approval
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at patients with mantle cell lymphoma who have already received a treatment called lisocabtagene maraleucel (Liso-cel) as part of standard care. It helps researchers understand how well the therapy works in real-world use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with mantle cell lymphoma (MCL).
- You have received at least one dose of Liso-cel (also called Breyanzi) for your MCL after it was approved by the FDA.
- Your Liso-cel dose was given according to the standard FDA-approved instructions.
- You are not taking part in any other research studies at the time you got Liso-cel.
- Your Liso-cel product met the commercial release standards in the US.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell therapy for people with high-risk mantle cell lymphoma that hasn't gotten worse after initial treatment. It aims to see if this targeted immunotherapy can improve outcomes for patients with aggressive disease features.
This trial tests a new combination of two targeted drugs for people with mantle cell lymphoma that has not responded to or has returned after treatment with a BTK inhibitor. The drugs aim to block cancer cell growth and survival pathways to potentially control the disease.
This trial tests a combination of three drugs (orelabrutinib, lisaftoclax, and rituximab) for people with mantle cell lymphoma who have not had treatment before and have high-risk features. The goal is to see if this combination works better than standard treatments.
This trial is testing a combination of two targeted drugs, orelabrutinib and rituximab, as a first treatment for mantle cell lymphoma (MCL). Some patients may also get a stem cell transplant. The goal is to see how well this approach works.
This trial tests a combination of two treatments: a CAR-T cell therapy (relmacabtagene autoleucel) and an immunotherapy drug (sintilimab) for people with certain types of B-cell lymphoma that have come back or stopped responding to other treatments. The goal is to see if this combination can help control the cancer.
This study looks at patients with a type of lymphoma (follicular lymphoma) who have already received a CAR T-cell therapy called liso-cel. Researchers want to track their health over time and see how well the treatment works and how safe it is in routine medical care.
Hear when a new Mantle Cell Lymphoma (MCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.